Riociguat is used for
**Core Concept**
Riociguat is a novel therapeutic agent that acts as a soluble guanylate cyclase (sGC) stimulator. This pharmacological action leads to an increase in cyclic guanosine monophosphate (cGMP) levels, which ultimately results in vasodilation and improved exercise capacity in patients with certain pulmonary and systemic vascular diseases.
**Why the Correct Answer is Right**
Riociguat works by binding to and stimulating sGC, independent of its nitric oxide (NO) binding site. This leads to a conformational change in the enzyme, resulting in increased guanylate cyclase activity and subsequent production of cGMP. The increase in cGMP levels activates protein kinase G (PKG), which in turn mediates vasodilation and improves exercise capacity in patients with pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH).
**Why Each Wrong Option is Incorrect**
**Option A:** This option is incorrect as riociguat is not primarily used for treating heart failure.
**Option B:** This option is incorrect as riociguat is not a phosphodiesterase-5 (PDE5) inhibitor like sildenafil.
**Option C:** This option is incorrect as riociguat is not a direct NO donor like nitroglycerin.
**Clinical Pearl / High-Yield Fact**
Riociguat is the first sGC stimulator to be approved for the treatment of PAH and CTEPH, offering a novel therapeutic option for patients with these diseases. Its unique mechanism of action provides a distinct advantage over other vasodilators, making it an important addition to the treatment armamentarium for these conditions.
**Correct Answer: D. Pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH).